MCET News MultiCell Technologies CEO to Present Key Research Data at New York Academy of Sciences' Animal Models Conference
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET),
developing first-in-class drugs based on advanced immune system
modulation and other proprietary technologies, today announced that
Chief Executive Officer Dr. Stephen Chang will be one of the featured
presenters this week at the New York Academy of Sciences (NYAS)
conference to explore new treatments for type-1 diabetes and multiple
sclerosis (MS).
MultiCell is a leader in the development of novel methods to modulate
the immune system to provide potential new treatments for a number of
major health threats and unmet medical needs. In particular, MultiCell
is focused on the development of MCT-125 and MCT-275. MCT-125 is a
first-in-class drug for treatment of chronic fatigue in patients with
multiple sclerosis. Currently there are no FDA approved drugs for the
treatment of fatigue in patients with MS. MCT-275, also a first-in-class
patent protected therapeutic, is indicated for the treatment of early
on-set type-1 diabetes. In preclinical animal modes, MCT-275 lowered
blood sugar levels to within normal range, and prevented death in the
experimental group compared to the control group where all animals died
as a result of the excessive blood sugar levels.
The New York Academy of Sciences conference, entitled, “How
do We Best Employ Animal Models for Type 1 Diabetes and Multiple
Sclerosis,” is scheduled for November 8-9,
2006.
“Our innovative immune modulation technologies
are enabling us to advance MCT-175 and MCT-275 as much-needed medical
treatments,” said Dr. Chang. “We
are very excited about sharing our data with our colleagues and building
on the momentum we have built over the past year, as we continue to
drive the next generation of autoimmune-based therapies to the bedside.”
Dr. Chang’s presentation, entitled, “A
Translational Perspective on New Technology,”
is scheduled for 11:00 am, Nov. 8. The meeting will take place at the
Stanford Court hotel in San Francisco, CA.
Among the topics of discussion, Dr. Chang will highlight MultiCell's
therapeutic pipeline with drug candidates already in various advanced
stages of human clinical trials. MCT-125 targets the chronic fatigue
symptom in MS patients, while MCT-175 is being developed as a treatment
of relapsing-remitting MS. MCT-275 for the treatment of early onset
type-1 diabetes.
The conference proceedings will be published as a volume of the Annals
of the New York Academy of Sciences, a series with a substantial
international circulation. The Annals are disseminated globally
to scientific, medical, and educational institutions and libraries, and
are also available to Academy members and other interested professionals
and students. The Institute for Scientific Information rates the Annals
in the top 2 percent of more than 4,000 scientific publications.
Established in 1817, NYAS has more than 23,000 members in more than 150
countries, with an ever-expanding international membership. Part of the
reason for this success is the collection of eBriefings –
digital versions of meetings like the one Dr. Chang will be presenting.
These eBriefings are not only a major NYAS asset but are also a
cutting-edge tool for advancing scientific communication worldwide.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company
committed to the development of breakthrough therapeutics based on a
portfolio of therapeutic candidates and patented drug development
technology. MultiCell's drug development program is focused on
modulation of the immune system. The Company's lead drug candidates
include drugs to treat MS-related chronic fatigue, relapsing-remitting
multiple sclerosis, type-1 diabetes and infectious disease. The Company
also holds unique cell-based technology for use in drug discovery
screening applications, and is a leading producer of the cell lines
needed by the biotechnology industry to develop new drugs and
therapeutics.
Any statements in this press release about MultiCell's expectations,
beliefs, plans, objectives, assumptions or future events or performance
are not historical facts and are forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
These statements are often, but not always, made through the use of
words or phrases such as "believe," "will", "expect," "anticipate,"
"estimate," "intend," "plan," "forecast," "could" and "would." Examples
of such forward-looking statements include statements regarding
developing products that address unmet medical needs. MultiCell bases
these forward-looking statements on current expectations about future
events. They involve known and unknown risks, uncertainties and
assumptions that may cause actual results, levels of activity,
performance or achievements to differ materially from those expressed or
implied by any forward-looking statement. Some of the risks,
uncertainties and assumptions that could cause actual results to differ
materially from estimates or projections in the forward-looking
statement include, but are not limited to, the risk that we might not
achieve our anticipated clinical development milestones, receive
regulatory approval, or successfully commercialize our lead drug
candidates as expected, the market for our products will not grow as
expected, and the risk that our products will not achieve expectations.
For additional information about risks and uncertainties MultiCell
faces, see documents MultiCell files with the SEC, including MultiCell's
report on Form 10-KSB for the fiscal year ended November 30, 2005, and
all our quarterly and other periodic SEC filings. MultiCell claims the
protection of the safe harbor for forward-looking statements under the
Act and each assume no obligation and expressly disclaim any duty to
update any forward-looking statement to reflect events or circumstances
after the date of this news release or to reflect the occurrence of
subsequent events.
